{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:05:00Z","timestamp":1791461100443,"version":"4.3.4"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32401125"],"award-info":[{"award-number":["32401125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32271445"],"award-info":[{"award-number":["32271445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ling-Jun and Yun-Ling Scholars of Yunnan Province","award":["202005AB160003"],"award-info":[{"award-number":["202005AB160003"]}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFJQ0050"],"award-info":[{"award-number":["2024NSFJQ0050"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Fundamental Research Project","award":["202501CF070064"],"award-info":[{"award-number":["202501CF070064"]}]},{"DOI":"10.13039\/501100007846","name":"Yunnan Provincial Department of Education","doi-asserted-by":"publisher","award":["2024J0008"],"award-info":[{"award-number":["2024J0008"]}],"id":[{"id":"10.13039\/501100007846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFB3810004"],"award-info":[{"award-number":["2023YFB3810004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Key Research and Development Program of China"},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific Research Fund of Yunnan Provincial Department of Education"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioactmat.2025.06.038","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:18:23Z","timestamp":1751386703000},"page":"924-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Biomaterials nanoplatform-based tumor vaccines for immunotherapy"],"prefix":"10.1016","volume":"51","author":[{"given":"Zhilin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3536-1485","authenticated-orcid":false,"given":"Kui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib1","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib2","article-title":"Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy","volume":"19","author":"Huang","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s44222-023-00030-y","article-title":"Engineering cytokine therapeutics","volume":"1","author":"Deckers","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.apsb.2023.08.014","article-title":"Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy","volume":"14","author":"Lin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bioactmat.2025.06.038_bib6","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.7150\/thno.112475","article-title":"Nano drug delivery systems for advanced immune checkpoint blockade therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","article-title":"Next-generation cancer vaccines and emerging immunotherapy combinations","volume":"10","author":"Brandenburg","year":"2024","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41551-025-01343-6","article-title":"Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection","volume":"9","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","article-title":"Enhancing immunotherapy with tumour-responsive nanomaterials","author":"Linderman","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib11","first-page":"330","article-title":"Engineering customized nanovaccines for enhanced cancer immunotherapy","volume":"36","author":"Guo","year":"2024","journal-title":"Bioact. Mater."},{"issue":"15","key":"10.1016\/j.bioactmat.2025.06.038_bib12","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.7150\/thno.87854","article-title":"Stimuli-activatable nanomedicine meets cancer theranostics","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1670","article-title":"Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis","volume":"13","author":"Li","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jconrel.2020.08.064","article-title":"Functional gadolinium-based nanoscale systems for cancer theranostics","volume":"329","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib15","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.7150\/thno.97768","article-title":"Biomarker-driven molecular imaging probes in radiotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol. Aspects Med."},{"issue":"Pt A","key":"10.1016\/j.bioactmat.2025.06.038_bib17","article-title":"A recent perspective on designing tumor vaccines for tumor immunology","volume":"142","author":"Cao","year":"2024","journal-title":"Int. Immunopharmacol"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"23","key":"10.1016\/j.bioactmat.2025.06.038_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib21","article-title":"DNA vaccines as promising immuno-therapeutics against cancer: a new insight","volume":"15","author":"Shariati","year":"2024","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","article-title":"RNA vaccines for cancer: principles to practice","volume":"42","author":"Guasp","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.apsb.2023.07.025","article-title":"Advanced nano-based strategies for mRNA tumor vaccine","volume":"14","author":"Qu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib25","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3596","article-title":"The bright side of chemistry: exploring synthetic peptide-based anticancer vaccines","volume":"30","author":"D'Aniello","year":"2024","journal-title":"J. Pept. Sci."},{"issue":"20","key":"10.1016\/j.bioactmat.2025.06.038_bib27","doi-asserted-by":"crossref","first-page":"11420","DOI":"10.1021\/acs.chemrev.9b00833","article-title":"Chemical strategies to boost cancer vaccines","volume":"120","author":"Li","year":"2020","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094934","article-title":"Tumor-derived antigenic peptides as potential cancer vaccines","volume":"25","author":"Sotirov","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114107","article-title":"Nanovaccines with cell-derived components for cancer immunotherapy","volume":"182","author":"Meng","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"43","key":"10.1016\/j.bioactmat.2025.06.038_bib30","article-title":"Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells","volume":"33","author":"Ma","year":"2021","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.apsb.2022.09.017","article-title":"A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"34","key":"10.1016\/j.bioactmat.2025.06.038_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202401806","article-title":"Programmed lung metastasis immunotherapy via cascade\u2010responsive cell membrane\u2010mimetic copolymer\u2010wrapped Nanoraspberry\u2010Mediated Elesclomol\u2010Copper delivery","volume":"34","author":"Huynh","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"28","key":"10.1016\/j.bioactmat.2025.06.038_bib33","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1021\/acsnano.4c06183","article-title":"A self-cascade penetrating brain tumor immunotherapy mediated by near-infrared II cell membrane-disrupting nanoflakes via detained dendritic cells","volume":"18","author":"Yalamandala","year":"2024","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib34","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.apsb.2022.11.003","article-title":"Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor-associated macrophages","volume":"13","author":"Tong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.apsb.2023.10.006","article-title":"Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.apsb.2023.10.003","article-title":"Self-sufficient nanoparticles with dual-enzyme activity trigger radical storms and activate cascade-amplified antitumor immunologic responses","volume":"14","author":"Bai","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib37","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/acsnano.4c09525","article-title":"Reprogramming dysfunctional dendritic cells by a versatile catalytic dual oxide antigen-captured nanosponge for remotely enhancing lung metastasis immunotherapy","volume":"19","author":"Chiang","year":"2025","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib38","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.apsb.2024.03.010","article-title":"Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.bioactmat.2025.06.038_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib40","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.apsb.2024.06.003","article-title":"In situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib41","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155485","article-title":"Tumor antigen presentation and the associated signal transduction during carcinogenesis","volume":"261","author":"Naskar","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib43","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.ai.2023.07.001","article-title":"MHC cross-dressing in antigen presentation","volume":"159","author":"MacNabb","year":"2023","journal-title":"Adv. Immunol."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101848","article-title":"Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy","volume":"71","author":"Moussion","year":"2024","journal-title":"Semin. Immunol."},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib47","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2024.03.015","article-title":"Vaccine adjuvants: tailoring innate recognition to send the right message","volume":"57","author":"Lavelle","year":"2024","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bioactmat.2025.06.038_bib50","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1016\/j.apsb.2024.09.012","article-title":"Next-generation aluminum adjuvants: immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs","volume":"14","author":"Su","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175632","article-title":"Adjuvants approved for human use: what do we know and what do we need to know for designing good adjuvants?","volume":"945","author":"Reyes","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41568-022-00462-5","article-title":"Context-dependent functions of pattern recognition receptors in cancer","volume":"22","author":"Man","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib53","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.immuni.2024.03.014","article-title":"Control of adaptive immunity by pattern recognition receptors","volume":"57","author":"Carroll","year":"2024","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.549","article-title":"Toll-like receptors in health and disease","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding toll-like receptors: recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2297453","article-title":"Toll-like receptor agonists as cancer vaccine adjuvants","volume":"20","author":"Jeon","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56369-w","article-title":"De novo design of protein minibinder agonists of TLR3","volume":"16","author":"Adams","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102460","article-title":"Rethinking toll-like receptor signalling","volume":"91","author":"Bryant","year":"2024","journal-title":"Curr. Opin. Immunol."},{"issue":"27","key":"10.1016\/j.bioactmat.2025.06.038_bib59","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1039\/D0OB00942C","article-title":"TLR2 agonists and their structure-activity relationships","volume":"18","author":"Lu","year":"2020","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00739-5","article-title":"Toll-like receptor 3: a double-edged sword","volume":"13","author":"Hsieh","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010023","article-title":"Therapeutic targeting of TLR4 for inflammation, infection, and cancer: a perspective for disaccharide lipid A mimetics","volume":"16","author":"Heine","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib62","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-024-10146-y","article-title":"Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation","volume":"52","author":"Afzal","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib63","article-title":"The role of TRL7\/8 agonists in cancer therapy, with special emphasis on hematologic malignancies","volume":"11","author":"Le\u015bniak","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"42","key":"10.1016\/j.bioactmat.2025.06.038_bib64","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1039\/D4CC00792A","article-title":"Molecule engineering strategy of toll-like receptor 7\/8 agonists designed for potentiating immune stimuli activation","volume":"60","author":"Gu","year":"2024","journal-title":"Chem. Comm."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib65","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG oligonucleotides as vaccine adjuvants","volume":"2197","author":"Kayraklioglu","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib67","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat. Cancer"},{"issue":"19","key":"10.1016\/j.bioactmat.2025.06.038_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300260","article-title":"Nanoparticle-mediated STING activation for cancer immunotherapy","volume":"12","author":"Li","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.056","article-title":"Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy","volume":"381","author":"Peng","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217410","article-title":"STING in cancer immunoediting: modeling tumor-immune dynamics throughout cancer development","volume":"612","author":"Zhang","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib71","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.immuni.2024.02.019","article-title":"New frontiers in the cGAS-STING intracellular DNA-Sensing pathway","volume":"57","author":"Dvorkin","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semcancer.2024.08.007","article-title":"cGAS\/STING signalling pathway in senescence and oncogenesis","volume":"106\u2013107","author":"Yu","year":"2024","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114020","article-title":"Delivery of STING agonists for adjuvanting subunit vaccines","volume":"179","author":"Van Herck","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib74","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.molmed.2019.02.007","article-title":"Pharmacological modulation of the STING pathway for cancer immunotherapy","volume":"25","author":"Berger","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06922-7","article-title":"Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1","volume":"9","author":"Kato","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353336","article-title":"5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation","volume":"15","author":"Temizoz","year":"2024","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib78","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","article-title":"Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid","volume":"190","author":"Conlon","year":"2013","journal-title":"J. Immunol."},{"issue":"7736","key":"10.1016\/j.bioactmat.2025.06.038_bib79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41586-018-0705-y","article-title":"Design of amidobenzimidazole STING receptor agonists with systemic activity","volume":"564","author":"Ramanjulu","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib80","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.apsb.2024.02.006","article-title":"Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"6506","key":"10.1016\/j.bioactmat.2025.06.038_bib81","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-Activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"issue":"6506","key":"10.1016\/j.bioactmat.2025.06.038_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00554-y","article-title":"Cytosolic DNA sensing by cGAS: regulation, function, and human diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib84","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.immuni.2018.03.017","article-title":"Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses","volume":"48","author":"Wang","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib85","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2024.04.042","article-title":"Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy","volume":"370","author":"Yang","year":"2024","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108053","article-title":"Mn(2+) directly activates cGAS and structural analysis suggests Mn(2+) induces a noncanonical catalytic synthesis of 2'3'-cGAMP","volume":"32","author":"Zhao","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122695","article-title":"Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy","volume":"311","author":"Zhang","year":"2024","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib88","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.immuni.2016.03.002","article-title":"Chitosan: an adjuvant with an unanticipated STING","volume":"44","author":"Riteau","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib89","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2016.02.004","article-title":"The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-Dependent induction of type I interferons","volume":"44","author":"Carroll","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib90","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-Activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib91","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41551-020-00675-9","article-title":"Prolonged activation of innate immune pathways by a polyvalent STING agonist","volume":"5","author":"Li","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib92","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/acs.molpharmaceut.0c00487","article-title":"In vivo and in vitro potency of polyphosphazene immunoadjuvants with hepatitis C virus antigen and the role of their supramolecular assembly","volume":"18","author":"Andrianov","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib93","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2020.12.001","article-title":"Polyphosphazene immunoadjuvants: historical perspective and recent advances","volume":"329","author":"Andrianov","year":"2021","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bioactmat.2025.06.038_bib94","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.trecan.2024.03.003","article-title":"Nanomedicine to aid immunogenic cell death (ICD)-Based anticancer therapy","volume":"10","author":"Demuynck","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib95","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib96","first-page":"299","article-title":"A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody","volume":"21","author":"Li","year":"2023","journal-title":"Bioac. Mater."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41577-023-00894-6","article-title":"The multifunctional protein HMGB1: 50 years of discovery","volume":"23","author":"Tang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib98","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-03058-7","article-title":"Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds","volume":"23","author":"Amiri","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib100","article-title":"Orchestrating cancer therapy: recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments","volume":"30","author":"Xu","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2023.09.044","article-title":"A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3","volume":"363","author":"Feng","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib102","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jconrel.2023.03.015","article-title":"Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy","volume":"356","author":"Zhang","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib103","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.apsb.2021.05.003","article-title":"GSH-Sensitive polymeric prodrug: synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine","volume":"12","author":"Luo","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib104","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.apsb.2020.07.023","article-title":"Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment","volume":"11","author":"Cai","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jconrel.2019.12.017","article-title":"Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis","volume":"318","author":"Luo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113604","article-title":"A nasally administrated reactive oxygen species-responsive carrier-free gene delivery nanosystem for alzheimer's disease combination therapy","volume":"381","author":"Chen","year":"2025","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib107","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1016\/j.apsb.2024.10.015","article-title":"Recent advances in reactive oxygen species (ROS)-Responsive drug delivery systems for photodynamic therapy of cancer","volume":"14","author":"Hu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib108","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.apsb.2024.06.015","article-title":"Transepithelial transport of nanoparticles in oral drug delivery: from the perspective of surface and holistic property modulation","volume":"14","author":"Zheng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib109","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.apsb.2025.03.016","article-title":"Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation","volume":"15","author":"Lin","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2024.11.018","article-title":"Autophagy-activating aluminum hydroxide nanovaccine for enhanced antigen presentation and anti-tumor immunity","volume":"377","author":"Chen","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00602-1","article-title":"Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects","volume":"14","author":"Cheng","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib112","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.apsb.2023.02.009","article-title":"Sequential delivery of PD-1\/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome","volume":"13","author":"Hu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib113","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","article-title":"Surface modification of lipid-based nanoparticles","volume":"16","author":"Xu","year":"2022","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202305300","article-title":"Lipid nanoparticles optimized for targeting and release of nucleic acid","volume":"36","author":"Jia","year":"2024","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib116","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib117","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.apsb.2022.11.013","article-title":"An mRNA vaccine elicits STING-Dependent antitumor immune responses","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.bioactmat.2025.06.038_bib118","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A. A."},{"issue":"17","key":"10.1016\/j.bioactmat.2025.06.038_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib120","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1039\/C9BM01564G","article-title":"Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy","volume":"8","author":"Lee","year":"2020","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib121","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-Mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2023.03.041","article-title":"Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses","volume":"357","author":"Pan","year":"2023","journal-title":"J. Control. Release"},{"issue":"20","key":"10.1016\/j.bioactmat.2025.06.038_bib123","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1021\/acs.nanolett.2c03234","article-title":"Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs","volume":"22","author":"Luozhong","year":"2022","journal-title":"Nano Lett."},{"issue":"45","key":"10.1016\/j.bioactmat.2025.06.038_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202303795","article-title":"Harnessing topology and stereochemistry of glycidylamine\u2010derived lipid nanoparticles for in vivo mRNA delivery to immune cells in spleen and their application for cancer vaccination","volume":"33","author":"Abd Elwakil","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"34","key":"10.1016\/j.bioactmat.2025.06.038_bib125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib126","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib127","article-title":"Advances and applications of nanoparticles in cancer therapy","volume":"3","author":"Huang","year":"2024","journal-title":"MedComm\u2013Oncol."},{"issue":"18","key":"10.1016\/j.bioactmat.2025.06.038_bib128","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202200194","article-title":"Nanomaterials based on functional polymers for sensitizing cancer radiotherapy","volume":"43","author":"Lin","year":"2022","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jconrel.2024.07.072","article-title":"A branched polymer-based agent for efficient and precise targeting of fibrosis diseases by magnetic resonance imaging","volume":"373","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"issue":"18","key":"10.1016\/j.bioactmat.2025.06.038_bib130","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/polym16182606","article-title":"Recent applications of PLGA in drug delivery systems","volume":"16","author":"Yang","year":"2024","journal-title":"Polymers"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119417","article-title":"Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines","volume":"220","author":"Da Silva","year":"2019","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002577","article-title":"Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized cancer immunotherapy","volume":"8","author":"Nam","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib133","first-page":"169","article-title":"Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy","volume":"26","author":"Su","year":"2023","journal-title":"Bioact. Mater."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib134","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1021\/acsnano.4c11014","article-title":"Personalized nanovaccine based on STING-activating nanocarrier for robust cancer immunotherapy","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biomaterials.2018.07.052","article-title":"Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines","volume":"182","author":"Qiu","year":"2018","journal-title":"Biomaterials"},{"issue":"23","key":"10.1016\/j.bioactmat.2025.06.038_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201895","article-title":"Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy","volume":"9","author":"Su","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2022.03.006","article-title":"Self-degradable poly(\u03b2-amino ester)s promote endosomal escape of antigen and agonist","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib138","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","article-title":"A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy","volume":"15","author":"Xu","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2022.140930","article-title":"Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines","volume":"456","author":"Li","year":"2023","journal-title":"Chem. Eng. J."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib140","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41565-020-00782-3","article-title":"Proton-driven transformable nanovaccine for cancer immunotherapy","volume":"15","author":"Gong","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121489","article-title":"Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity","volume":"284","author":"Xu","year":"2022","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031370","article-title":"Mannose ligands for mannose receptor targeting","volume":"25","author":"Paurevi\u0107","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bioactmat.2025.06.038_bib143","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1021\/acs.nanolett.0c01140","article-title":"Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Nano Lett."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib144","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101651","article-title":"Well-defined mannosylated polymer for peptide vaccine delivery with enhanced antitumor immunity","volume":"11","author":"Lv","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"6","key":"10.1016\/j.bioactmat.2025.06.038_bib145","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1039\/D2CS00352J","article-title":"Bioactive inorganic nanomaterials for cancer theranostics","volume":"52","author":"Pei","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.150067","article-title":"Functional inorganic nanomaterials for optical cancer theranostics","volume":"485","author":"Song","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"33","key":"10.1016\/j.bioactmat.2025.06.038_bib147","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1021\/acs.nanolett.4c02485","article-title":"Targeted inhibition of lymphovascular invasion formation with CREKA peptide-modified silicasomes to boost chemotherapy in bladder cancer","volume":"24","author":"Wu","year":"2024","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib148","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01654-7","article-title":"Multifunctional mesoporous silica nanoparticles for biomedical applications","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"25","key":"10.1016\/j.bioactmat.2025.06.038_bib149","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4462","article-title":"The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency","volume":"6","author":"Hong","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib150","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202305567","article-title":"Effects of skeleton structure of mesoporous silica nanoadjuvants on cancer immunotherapy","volume":"20","author":"Tan","year":"2024","journal-title":"Small"},{"issue":"32","key":"10.1016\/j.bioactmat.2025.06.038_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202270173","article-title":"Elastic nanovaccine enhances dendritic cell-mediated tumor immunotherapy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"issue":"26","key":"10.1016\/j.bioactmat.2025.06.038_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202200756","article-title":"Mesoporous silica materials as an emerging tool for cancer immunotherapy","volume":"9","author":"Escriche-Navarro","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119859","article-title":"Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen\/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold","volume":"239","author":"Nguyen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114534","article-title":"Hollow mesoporous silica nanoparticles for drug formulation and delivery: opportunities for cancer therapy","volume":"249","author":"Guo","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"31","key":"10.1016\/j.bioactmat.2025.06.038_bib155","doi-asserted-by":"crossref","first-page":"34658","DOI":"10.1021\/acsami.0c09484","article-title":"Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine","volume":"12","author":"Lee","year":"2020","journal-title":"ACS Appl. Mater. & Inter."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib156","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/acs.molpharmaceut.0c00802","article-title":"Metal-phenolic network-encapsulated nanovaccine with pH and reduction dual responsiveness for enhanced cancer immunotherapy","volume":"17","author":"Zhou","year":"2020","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib157","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-025-03252-x","article-title":"Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives","volume":"23","author":"Guo","year":"2025","journal-title":"J. Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib158","article-title":"Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy","volume":"20","author":"Wang","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"issue":"35","key":"10.1016\/j.bioactmat.2025.06.038_bib159","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1002\/adfm.201600650","article-title":"Metal\u2010organic\u2010framework\u2010based vaccine platforms for enhanced systemic immune and memory response","volume":"26","author":"Zhang","year":"2016","journal-title":"Adv. Funct. Mater."},{"issue":"27","key":"10.1016\/j.bioactmat.2025.06.038_bib160","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302967","article-title":"Zinc-organometallic framework vaccine controlled-release Zn(2+) regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy","volume":"10","author":"Ding","year":"2023","journal-title":"Adv. Sci."},{"issue":"39","key":"10.1016\/j.bioactmat.2025.06.038_bib161","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.2174\/0109298673251648231106112354","article-title":"Application research progress of nanomaterial graphene and its derivative complexes in tumor diagnosis and therapy","volume":"31","author":"Cui","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib162","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1016\/j.cclet.2022.01.071","article-title":"A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy","volume":"33","author":"Zhang","year":"2022","journal-title":"Chin. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib163","doi-asserted-by":"crossref","first-page":"13268","DOI":"10.1021\/acsnano.0c05062","article-title":"Efficient lymph node-targeted delivery of personalized cancer vaccines with reactive oxygen species-inducing reduced graphene oxide nanosheets","volume":"14","author":"Xu","year":"2020","journal-title":"ACS Nano"},{"issue":"37","key":"10.1016\/j.bioactmat.2025.06.038_bib164","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202301420","article-title":"Construction of ph-sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy","volume":"19","author":"Ding","year":"2023","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib165","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.apsb.2023.08.027","article-title":"Unlocking the potential of amorphous calcium carbonate: a star ascending in the realm of biomedical application","volume":"14","author":"Liu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib166","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1021\/acs.chemmater.6b05062","article-title":"Cancer cell lysate entrapment in CaCO3 engineered with polymeric TLR-agonists: immune-modulating microparticles in view of personalized antitumor vaccination","volume":"29","author":"Lybaert","year":"2017","journal-title":"Chem. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114006","article-title":"Engineering of stimuli-responsive self-assembled biomimetic nanoparticles","volume":"179","author":"Krishnan","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125336","article-title":"Cell membrane-camouflaged nanocarriers: a cutting-edge biomimetic technology to develop cancer immunotherapy","volume":"672","author":"Samanta","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.bioactmat.2025.06.038_bib170","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bioactmat.2025.06.038_bib171","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.apsb.2023.03.004","article-title":"Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis","volume":"13","author":"Zhu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib172","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.apsb.2022.02.023","article-title":"Cell membrane coated-nanoparticles for cancer immunotherapy","volume":"12","author":"Zeng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib173","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/acsnano.2c09033","article-title":"Tumor-antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma","volume":"17","author":"Ma","year":"2023","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib174","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/acs.biomac.0c00518","article-title":"pH-Responsive biomimetic polymeric micelles as lymph node-targeting vaccines for enhanced antitumor immune responses","volume":"21","author":"Yang","year":"2020","journal-title":"Biomacromolecules"},{"issue":"Pt A","key":"10.1016\/j.bioactmat.2025.06.038_bib175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijbiomac.2020.09.187","article-title":"PEI-Modified macrophage cell membrane-coated PLGA nanoparticles encapsulating dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses","volume":"165","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib176","article-title":"Systematic design of cell membrane coating to improve tumor targeting of nanoparticles","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.bioactmat.2025.06.038_bib177","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1021\/acs.nanolett.1c03004","article-title":"Personalized nanovaccine coated with Calcinetin-Expressed cancer cell membrane antigen for cancer immunotherapy","volume":"21","author":"Xiong","year":"2021","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24010172","article-title":"Click chemistry as a tool for cell engineering and drug delivery","volume":"24","author":"Takayama","year":"2019","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.bioactmat.2025.06.038_bib179","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1002\/asia.202100852","article-title":"Recent progress and perspectives on cell surface modification","volume":"16","author":"Zhang","year":"2021","journal-title":"Chem. Asian J."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib180","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acs.nanolett.0c04783","article-title":"Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy","volume":"21","author":"Xiao","year":"2021","journal-title":"Nano Lett."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib181","doi-asserted-by":"crossref","DOI":"10.3390\/nano14050413","article-title":"Engineered cell membrane-camouflaged nanomaterials for biomedical applications","volume":"14","author":"Guan","year":"2024","journal-title":"Nanomaterials"},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib182","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","article-title":"Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma","volume":"9","author":"Guo","year":"2015","journal-title":"ACS Nano"},{"issue":"22","key":"10.1016\/j.bioactmat.2025.06.038_bib183","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1021\/acs.nanolett.1c02582","article-title":"Equipping cancer cell membrane vesicles with functional DNA as a targeted vaccine for cancer immunotherapy","volume":"21","author":"Liu","year":"2021","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.bioactmat.2025.06.038_bib184","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","article-title":"T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy","volume":"16","author":"Zhai","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"30","key":"10.1016\/j.bioactmat.2025.06.038_bib185","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202001808","article-title":"Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity","volume":"32","author":"Jiang","year":"2020","journal-title":"Adv. Mater."},{"issue":"13","key":"10.1016\/j.bioactmat.2025.06.038_bib186","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202208923","article-title":"Tumor cell nanovaccines based on genetically engineered antibody-anchored membrane","volume":"35","author":"Li","year":"2023","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib187","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18626-y","article-title":"Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis","volume":"11","author":"Rao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2020.05.028","article-title":"Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy","volume":"112","author":"Chen","year":"2020","journal-title":"Acta Biomater."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib189","doi-asserted-by":"crossref","DOI":"10.1002\/sstr.202300473","article-title":"Hybrid cell membrane\u2010coated nanoparticles for biomedical applications","volume":"5","author":"Yu","year":"2024","journal-title":"Small Struct."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib190","article-title":"Development of a dendritic cell\/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib191","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jconrel.2023.11.057","article-title":"Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications","volume":"365","author":"Yang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116699","article-title":"Exosomes as carriers to stimulate an anti-cancer immune response in immunotherapy and as predictive markers","volume":"232","author":"Nie","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib193","first-page":"445","article-title":"Enhancing drug penetration in solid tumors via nanomedicine: evaluation models, strategies and perspectives","volume":"32","author":"Shen","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib194","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2023.07.059","article-title":"Extracellular vesicle-embedded materials","volume":"361","author":"Ma","year":"2023","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082070","article-title":"Dendritic cell-derived exosomes in cancer immunotherapy","volume":"15","author":"Luo","year":"2023","journal-title":"Pharmaceutics"},{"issue":"15","key":"10.1016\/j.bioactmat.2025.06.038_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153667","article-title":"DC-Derived exosomes for cancer immunotherapy","volume":"13","author":"Yao","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib197","doi-asserted-by":"crossref","DOI":"10.1038\/srep17622","article-title":"TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma","volume":"5","author":"Damo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib198","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","article-title":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","volume":"353","author":"Li","year":"2023","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib199","article-title":"Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103639","article-title":"Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment","volume":"25","author":"Lv","year":"2022","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib201","doi-asserted-by":"crossref","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2024.02.05","article-title":"New roles of tumor-derived exosomes in tumor microenvironment","volume":"36","author":"Chen","year":"2024","journal-title":"Chin. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib202","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib203","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1021\/acsnano.4c01050","article-title":"Biologically self-assembled tumor cell-derived cancer nanovaccines as an all-in-one platform for cancer immunotherapy","volume":"18","author":"Liang","year":"2024","journal-title":"ACS Nano"},{"issue":"615","key":"10.1016\/j.bioactmat.2025.06.038_bib204","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6981","article-title":"Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114321","article-title":"Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy","volume":"186","author":"Long","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib206","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1039\/D4TB01899K","article-title":"Bacterial outer membrane vesicles in tumor prevention and treatment: advancements in research and application","volume":"13","author":"Liu","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib207","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jconrel.2020.04.031","article-title":"Bacterial outer membrane vesicles as a platform for biomedical applications: an update","volume":"323","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"issue":"14","key":"10.1016\/j.bioactmat.2025.06.038_bib208","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202107461","article-title":"Antigen capture and immune modulation by bacterial outer membrane vesicles as in situ vaccine for cancer immunotherapy post-photothermal therapy","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"issue":"43","key":"10.1016\/j.bioactmat.2025.06.038_bib209","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902626","article-title":"Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.bioactmat.2025.06.038_bib210","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","article-title":"Nanocarriers based on bacterial membrane materials for cancer vaccine delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.06.038_bib211","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a rugged nanoscaffold to enhance plug-and-display vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib212","article-title":"Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology","volume":"12","author":"Cheng","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib213","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsnano.2c08880","article-title":"Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis","volume":"17","author":"Ma","year":"2023","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202413392","article-title":"An OMV-based nanovaccine as antigen presentation signal enhancer for cancer immunotherapy","volume":"37","author":"Lu","year":"2025","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib215","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","article-title":"Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria","volume":"6","author":"Yue","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"20","key":"10.1016\/j.bioactmat.2025.06.038_bib216","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109984","article-title":"Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib217","article-title":"Oral administration of cancer vaccines: challenges and future perspectives","volume":"12","author":"Gambirasi","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib218","doi-asserted-by":"crossref","DOI":"10.3390\/gels10040262","article-title":"Advances in hydrogel-based drug delivery systems","volume":"10","author":"Liu","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2025.103470","article-title":"Smart hydrogel: a new platform for cancer therapy","volume":"340","author":"Guo","year":"2025","journal-title":"Adv. Colloid Interface Sci."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib220","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-024-02786-x","article-title":"A comprehensive review of hydrogel-based drug delivery systems: classification, properties, recent trends, and applications","volume":"25","author":"Hameed","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"47","key":"10.1016\/j.bioactmat.2025.06.038_bib221","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adc8738","article-title":"Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy","volume":"8","author":"Lei","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139151","article-title":"A review of sodium alginate-based hydrogels: structure, mechanisms, applications, and perspectives","volume":"292","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"29","key":"10.1016\/j.bioactmat.2025.06.038_bib223","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202201306","article-title":"Bifunctional fusion membrane\u2010based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells","volume":"32","author":"Ke","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib224","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.actbio.2023.08.010","article-title":"A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel","volume":"169","author":"Nie","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122147","article-title":"A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy","volume":"299","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"issue":"49","key":"10.1016\/j.bioactmat.2025.06.038_bib226","doi-asserted-by":"crossref","first-page":"2306554","DOI":"10.1002\/adfm.202306554","article-title":"Tailoring hyaluronic acid hydrogels for biomedical applications","volume":"33","author":"Luo","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib227","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202204636","article-title":"Stabilizing RNA nanovaccines with transformable hyaluronan dynamic hydrogel for durable cancer immunotherapy","volume":"33","author":"Jia","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"40","key":"10.1016\/j.bioactmat.2025.06.038_bib228","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202206084","article-title":"Unified therapeutic\u2010prophylactic vaccine demonstrated with a postoperative filler gel to prevent tumor recurrence and metastasis","volume":"32","author":"Cao","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib229","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.actbio.2022.12.070","article-title":"Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy","volume":"158","author":"Song","year":"2023","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib230","article-title":"Recent advances on thermosensitive hydrogels-mediated precision therapy","volume":"19","author":"Chen","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/gels9070523","article-title":"Polymer-based hydrogels applied in drug delivery: an overview","volume":"9","author":"Thang","year":"2023","journal-title":"Gels"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib232","article-title":"A biodegradable thermosensitive hydrogel vaccine for cancer immunotherapy","volume":"19","author":"Yang","year":"2020","journal-title":"Appl. Mater. Today"},{"issue":"15","key":"10.1016\/j.bioactmat.2025.06.038_bib233","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202170099","article-title":"Injection of ROS\u2010responsive hydrogel loaded with basic fibroblast growth factor into the pericardial cavity for heart repair","volume":"31","author":"Li","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib234","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2022.09.027","article-title":"A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors","volume":"351","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122218","article-title":"Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination","volume":"301","author":"He","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib236","article-title":"Natural blood plasma-based hydrogels as tumor vaccines delivery systems to enhance biomimetic recruitment of antigen presenting cells for tumor immunotherapy","volume":"17","author":"Huang","year":"2022","journal-title":"Mater. Today Bio"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib237","doi-asserted-by":"crossref","DOI":"10.1007\/s00203-023-03480-5","article-title":"Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)","volume":"205","author":"Baghban","year":"2023","journal-title":"Arch. Microbiol."},{"issue":"11","key":"10.1016\/j.bioactmat.2025.06.038_bib238","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.70053","article-title":"New insights for the development of efficient DNA vaccines","volume":"17","author":"Berger","year":"2024","journal-title":"Microb. Biotechnol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib239","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115190","article-title":"mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond","volume":"206","author":"Estap\u00e9 Senti","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.bioactmat.2025.06.038_bib241","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"Pt 4","key":"10.1016\/j.bioactmat.2025.06.038_bib242","article-title":"Old concepts, new tricks: how peptide vaccines are reshaping cancer immunotherapy?","volume":"279","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib243","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7150\/jca.88261","article-title":"Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy","volume":"15","author":"Tong","year":"2024","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib244","first-page":"A1","article-title":"289PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting","volume":"8","author":"Thomas Marron","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib245","article-title":"Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer","volume":"42","author":"Jonathan Forrest Anker","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7662","key":"10.1016\/j.bioactmat.2025.06.038_bib246","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib247","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2323256","article-title":"Utility of cell-based vaccines as cancer therapy: systematic review and meta-analysis","volume":"20","author":"Tiwari","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib248","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib249","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bioactmat.2025.06.038_bib250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052594","article-title":"Identification of neoantigens in cancer cells as targets for immunotherapy","volume":"23","author":"Okada","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioactmat.2025.06.038_bib251","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/D3CS00162H","article-title":"Advancing nanotechnology for neoantigen-based cancer theranostics","volume":"53","author":"Zou","year":"2024","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.06.038_bib252","doi-asserted-by":"crossref","DOI":"10.7150\/thno.104872","article-title":"Metformin-based nanomedicines for reprogramming tumor immune microenvironment","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib253","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/med.22016","article-title":"cGAS-STING pathway agonists are promising vaccine adjuvants","volume":"44","author":"Tian","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.bioactmat.2025.06.038_bib255","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2022.11.001","article-title":"Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.06.038_bib256","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib257","article-title":"Tumor immunotherapy: mechanisms and clinical applications","volume":"1","author":"Nong","year":"2022","journal-title":"MedComm\u2013Oncol"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113603","article-title":"Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy","volume":"381","author":"Zhu","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib259","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02004-z","article-title":"Neutrophils in cancer immunotherapy: friends or foes?","volume":"23","author":"Huang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioactmat.2025.06.038_bib260","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","article-title":"The advent of immune stimulating CAFs in cancer","volume":"23","author":"Tsoumakidou","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2025.06.038_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113606","article-title":"Stimuli-responsive polymer-dasatinib prodrug to reprogram cancer-associated fibroblasts for boosted immunotherapy","volume":"381","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"issue":"728","key":"10.1016\/j.bioactmat.2025.06.038_bib262","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib263","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm\u2013Oncol"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.06.038_bib264","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.apsb.2024.12.007","article-title":"Recent advances in the bench-to-bedside translation of cancer nanomedicines","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.bioactmat.2025.06.038_bib265","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2025.06.038_bib266","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2023.01.005","article-title":"Artificial intelligence aids in development of nanomedicines for cancer management","volume":"89","author":"Tan","year":"2023","journal-title":"Semin. Cancer Biol."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X25002749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X25002749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:49:17Z","timestamp":1756856957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X25002749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":266,"alternative-id":["S2452199X25002749"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2025.06.038","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomaterials nanoplatform-based tumor vaccines for immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2025.06.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}